Pleurectomy vs. Extrapleural Pneumonectomy: 5-Year Survival Rates & Recovery Timelines for Mesothelioma

What Is Pleurectomy/Decortication and How Does It Work?

Pleurectomy/decortication—often abbreviated P/D—is a lung-sparing surgical procedure designed to remove the pleura (the thin membrane lining the chest wall and surrounding the lungs) and all visible mesothelioma tumors without removing the lung itself. The procedure preserves lung tissue and breathing capacity, making it fundamentally different from EPP.

During P/D, the surgeon makes an incision along the ribs, carefully separates the pleural lining from the lung surface, and removes it along with any adherent tumors. The pericardium (the sac around the heart) and diaphragm (the breathing muscle) are preserved—only the diseased pleura is removed. For patients with early-stage epithelioid mesothelioma, this approach removes most visible disease while maintaining respiratory function.

"Pleurectomy/decortication has become the standard surgical approach at leading mesothelioma centers. It delivers survival outcomes competitive with more aggressive surgery, with substantially lower operative risk and superior quality of life. For patients diagnosed today, P/D is the default conversation—not an alternative." — David Foster, Executive Director of Client Services, Danziger & De Llano

The procedure typically takes 3–4 hours and is often paired with intraoperative heated chemotherapy (hyperthermic intracavitary chemotherapy, or HICCE) to bathe the cavity and kill remaining cancer cells. Modern variations include extended pleurectomy/decortication, which removes more parietal tissue and mediastinal pleura than standard P/D, closing the gap between conservative and aggressive surgery without sacrificing the lung.

What Is Extrapleural Pneumonectomy and What Does Surgical Removal Include?

Extrapleural pneumonectomy (EPP) is the most aggressive surgical approach to mesothelioma. Rather than sparing the lung, EPP removes the entire affected lung, the pleural lining, the diaphragm, and the pericardium in a single block resection. This en bloc removal aims to eliminate all gross disease in one operation, including the primary tumor and involved structures.

The procedure is performed through a large incision between the ribs, and the surgeon systematically removes all five components: the lung, pleura, diaphragm, pericardium, and any involved mediastinal tissue. The diaphragm is reconstructed using a synthetic patch (usually Gore-Tex), and the pericardium is repaired or patched to restore the heart's protective envelope.

EPP is a major surgery requiring 4–6 hours in the operating room. Most modern mesothelioma centers reserve EPP for younger, highly fit patients with favorable histology (epithelioid type), early stage disease, and no significant comorbidities. The trade-off is clear: EPP's aggressive removal may treat more disease, but it comes with higher operative mortality, longer recovery, and permanent loss of lung function on one side. [3]

How Do Median Survival Rates Compare Between the Two Procedures?

Historically, surgical outcomes were difficult to compare because patient selection differed significantly—EPP candidates were often younger and more fit than P/D candidates. Modern data from high-volume centers reveals an important reversal: pleurectomy/decortication achieves superior or equivalent median survival compared to EPP.

Pleurectomy/Decortication Survival: Large retrospective series report median overall survival of 18–23 months when combined with chemotherapy. Some single-institution studies exceed 24 months. The median survival improves significantly when patients receive multimodal therapy (surgery + pemetrexed/cisplatin chemotherapy), with some cohorts reaching 36+ months.

Extrapleural Pneumonectomy Survival: EPP historical series reported median survival of 12–18 months, with some studies citing 16–20 months in highly selected cohorts. The UK's landmark MARS trial (2014) randomized mesothelioma patients to EPP plus chemotherapy versus chemotherapy alone—finding no survival advantage for EPP and increased morbidity. This pivotal trial shifted the surgical consensus away from routine EPP.

"The MARS trial was a game-changer. It showed that more aggressive surgery doesn't automatically mean better survival—and that preserving the lung and quality of life is at least as valuable as extensive tissue removal. That data accelerated the field's migration toward pleurectomy as the preferred approach." — David Foster, Executive Director of Client Services, Danziger & De Llano

The bottom line: modern evidence shows P/D and EPP deliver similar median survival, with P/D offering lower operative mortality and superior long-term quality of life.

What Are the Operative Mortality Rates and In-Hospital Complication Risks?

When evaluating surgery for mesothelioma, operative mortality—death in the hospital or within 30 days of surgery—is a critical metric. The disparity between P/D and EPP is substantial and clearly favors the lung-sparing approach.

Pleurectomy/Decortication: Operative mortality ranges from 1–4% across major cancer centers. At high-volume mesothelioma centers (those performing 100+ mesothelioma surgeries annually), P/D mortality often falls below 2%. Major complications include prolonged air leak, infection, arrhythmia, and respiratory insufficiency, but the overall safety profile is favorable.

Extrapleural Pneumonectomy: EPP operative mortality ranges from 5–7%, with some early series reporting rates as high as 8–10%. The higher risk reflects the procedure's complexity, the removal of the diaphragm and pericardium, and the permanent loss of lung function. Complications include acute respiratory distress syndrome (ARDS), prolonged intubation, cardiac arrhythmia, bronchopleural fistula, and sepsis.

For context: a 3-point difference in operative mortality (1–4% vs. 5–7%) is substantial in surgical terms. Among 100 mesothelioma patients, approximately 1–4 would die from P/D, while 5–7 would die from EPP. This gap, combined with equivalent survival outcomes, is a primary reason leading surgical oncologists now recommend pleurectomy as the first-line surgical approach.

What Is the Recovery Timeline After Pleurectomy Surgery?

Recovery from pleurectomy/decortication is relatively rapid compared to EPP, making it attractive for patients concerned about time away from family, work, or other treatments.

Hospital Stay: Most P/D patients are discharged within 7–10 days if recovery progresses smoothly. Some centers achieve 5–7-day stays with enhanced recovery protocols. A chest tube typically remains for 3–7 days to drain fluid from the surgical space.

First 2–4 Weeks: Patients can walk, light stretching, and gradual increase in activity are encouraged. Pain management typically uses oral medications by week 2–3. Breathing exercises and physical therapy begin immediately to prevent complications and restore lung function. Most patients can drive short distances by week 3–4 if pain is controlled and narcotic use has ceased.

Weeks 4–6: Return to light activities, including desk work and supervised exercise. Many patients resume gentle aerobic activity (walking 20–30 minutes) by week 6. Full return to heavy lifting and high-impact activities typically takes 8–12 weeks.

3–6 Months: Most P/D patients are fully recovered and return to their baseline activity level. Fatigue may persist for some, but pulmonary function is usually restored. Chemotherapy is typically started 4–6 weeks after surgery if not done prior to P/D.

What Is the Recovery Timeline After Extrapleural Pneumonectomy?

Recovery from EPP is significantly longer and more challenging than P/D, reflecting the magnitude of tissue removal and the permanent change in respiratory physiology.

Hospital Stay: EPP patients typically remain hospitalized for 10–14 days, with some requiring 3–4 weeks if complications arise. Ventilatory support (intubation) is sometimes needed for several days after surgery. A chest tube remains for 7–14 days or longer.

First 4 Weeks: Recovery is slower and pain management is more demanding. Patients remain limited in activity, with short walks supervised by a physical therapist. Breathing is harder due to the loss of the entire lung on one side, and most patients experience shortness of breath even at rest initially. Returning home often requires in-home support or rehabilitation facility placement.

Weeks 4–12: Gradual increase in activity, with most patients able to walk 20–30 minutes by week 8–10. Return to sedentary work may be possible by week 8, but full activity recovery typically takes 12–16 weeks. Patients must live with permanent pulmonary compromise—breathing capacity is permanently reduced by roughly 30–40% due to the single lung.

3–6 Months and Beyond: Full functional recovery can take 4–6 months or longer. Many EPP patients report lasting fatigue and dyspnea (shortness of breath) with exertion. Chemotherapy is delayed until the patient has recovered enough to tolerate systemic treatment—often 8–12 weeks postsurgery.

Which Surgery Is Right for Me? Patient Selection Criteria?

The choice between P/D and EPP is individualized and depends on several factors. Your surgical oncologist will evaluate disease stage, histology, pulmonary function, cardiac status, age, and overall performance status.

Pleurectomy/Decortication is preferred for:

• Patients with early-stage (Stage I–II) pleural mesothelioma
• Epithelioid or biphasic histology (non-sarcomatoid)
• Patients aged 65+ with good performance status
• Patients with marginal pulmonary reserve or comorbidities
• Patients prioritizing quality of life and rapid recovery
• Patients with adequate performance status to tolerate chemotherapy post-surgery

Extrapleural Pneumonectomy may be considered for:

• Younger patients (typically <65) with excellent cardiac and pulmonary function
• Fit patients with extensive mediastinal involvement (disease in the central chest)
• Highly motivated patients who understand the operative risks and quality-of-life trade-offs
• Cases where P/D is technically infeasible due to extensive disease burden

"Patient selection is nuanced, not algorithmic. We look at stage, histology, fitness, and—equally important—what the patient values. Some patients will choose EPP despite higher risk because they want the most aggressive approach. Others strongly prefer P/D because they want to preserve lung function and get back to their lives faster. Both are legitimate choices, made with full informed consent." — David Foster, Executive Director of Client Services, Danziger & De Llano

For most newly diagnosed patients today, the conversation begins with pleurectomy/decortication. EPP is reserved for carefully selected cases.

How Does Chemotherapy Factor Into Surgical Planning?

Surgery alone—whether P/D or EPP—is rarely recommended today. Multimodal therapy (surgery combined with chemotherapy, and sometimes radiation) is the gold standard. The timing and sequencing of chemotherapy relative to surgery matters significantly.

Neoadjuvant Chemotherapy: Some centers administer pemetrexed + cisplatin chemotherapy before surgery (typically 3–4 cycles) to shrink tumors and improve resectability. This approach allows surgeons to achieve more complete resection and may improve downstream survival. Patients tolerate this sequence well, though delaying surgery adds 2–3 months to treatment.

Adjuvant Chemotherapy: Most patients receive chemotherapy after surgery once they have recovered (typically 4–8 weeks post-op). This approach allows immediate surgical resection while the patient is freshly diagnosed, though some tumor burden remains at the time of surgery. [12]

Platinum-Based Regimen: The gold-standard chemotherapy for mesothelioma is pemetrexed (Alimta) combined with cisplatin, typically given intravenously every 3 weeks for 4–6 cycles. This combination has shown superior survival compared to other regimens. Some centers are exploring maintenance immunotherapy (e.g., bevacizumab) after platinum-based therapy, though data is still emerging. [13]

Your surgical oncology team will recommend the optimal sequence for your specific situation. Many mesothelioma patients qualify for financial compensation through asbestos trust funds, which can help cover the costs of multimodal therapy.

Are There Emerging Surgical Techniques or Clinical Trials?

Mesothelioma surgery continues to evolve. Several refinements and emerging approaches are reshaping the field:

Extended Pleurectomy/Decortication (EPD): This refinement of standard P/D removes more parietal pleura and mediastinal tissue than conventional P/D, narrowing the gap between conservative and aggressive approaches while still sparing the lung. Some surgeons use EPD as an alternative to EPP, achieving more complete disease removal with lower operative risk.

Hyperthermic Intracavitary Chemotherapy (HICCE): Heated chemotherapy delivered directly into the chest cavity during surgery has become standard at major mesothelioma centers. The heat enhances drug penetration into tissue, potentially improving local control and survival. Multiple studies support this intraoperative adjunct for both P/D and EPP.

Immunotherapy Integration: Clinical trials are exploring checkpoint inhibitors (nivolumab, pembrolizumab) combined with chemotherapy and surgery. Early data suggest potential survival benefits, though optimal sequencing is still being defined.

Video-Assisted Thoracoscopic Surgery (VATS): Some surgeons are exploring minimally invasive techniques for selected P/D cases, reducing recovery time and hospital stay compared to open thoracotomy. This approach is not yet standard but shows promise in early reports.

If you are diagnosed with mesothelioma, ask your surgical oncologist about available clinical trials. Active trials may offer access to novel approaches not yet widely available.

What Questions Should I Ask My Surgical Oncologist?

When meeting with your mesothelioma surgical team, come prepared with these critical questions:

• Which procedure do you recommend for my specific stage, histology, and fitness level—and why? The answer should reference your disease extent and your personal risk tolerance.
• What is your center's operative mortality and morbidity data for both P/D and EPP? Ask for recent institutional statistics, not national averages.
• How many mesothelioma surgeries does your team perform per year? High-volume centers (100+ per year) show better outcomes.
• When will chemotherapy start, and what regimen will I receive? Discuss neoadjuvant vs. adjuvant timing and whether combination therapies or immunotherapy are planned.
• What is my expected median survival with this treatment plan? Request individualized prognostic data based on your stage and cell type.
• What is your plan if I develop complications after surgery? Understand how your team manages postoperative issues like air leak or infection.
• Will I need radiation therapy, and if so, when? Some centers integrate postoperative radiation into multimodal plans.
• Are there clinical trials I should consider? Ask about immunotherapy trials, emerging surgical techniques, and other research opportunities.

Mesothelioma lawyers at our firm can also help you understand your legal options if your diagnosis resulted from workplace asbestos exposure.

How Can I Prepare Physically for Mesothelioma Surgery?

Preoperative optimization improves surgical outcomes. Work with your surgical team on these preparations:

• Pulmonary Function Testing (PFT): Testing measures lung capacity and helps predict postoperative respiratory function. It guides the choice between P/D and EPP.
• Cardiac Evaluation: EKG and echocardiography ensure your heart can tolerate surgery. Some patients require optimization of heart medications or rhythm management.
• Physical Therapy: Preoperative breathing exercises (incentive spirometry) and general conditioning improve surgical recovery. Even light walking daily helps.
• Smoking Cessation: If you smoke, quitting now dramatically reduces postoperative complications. Even brief cessation (2–4 weeks) helps.
• Nutritional Optimization: Protein intake should be adequate (aim for 1–1.2 g per kg body weight daily) to support wound healing. Discuss nutritional supplements with your team.
• Medication Review: Blood thinners and NSAIDs may need to be held before surgery. Discuss your current medications with your surgical team.

What Happens if Recurrence Occurs After Mesothelioma Surgery?

Unfortunately, mesothelioma recurs in many patients despite aggressive surgery and chemotherapy. Local recurrence (disease returning in the chest) is most common, followed by distant metastasis. Median time to recurrence is 8–14 months after surgery.

Salvage options for recurrent disease are limited but may include additional chemotherapy, radiation therapy, clinical trials, and in some cases, repeat surgery. Immunotherapy approaches are being investigated as salvage strategies. Always discuss recurrence risk and surveillance planning with your oncology team.

For patients facing mesothelioma diagnosis, veterans benefits and trust fund compensation may help cover treatment costs, including surgery, chemotherapy, and palliative care.

What Are the Critical Takeaways for Mesothelioma Surgery Decisions?

Pleurectomy/decortication and extrapleural pneumonectomy are the two surgical pillars of mesothelioma treatment. Modern evidence—particularly the MARS trial and retrospective series from major cancer centers—favors P/D as the standard surgical approach for most newly diagnosed patients. P/D achieves median survival of 18–23 months with lower operative mortality (1–4%), faster recovery (4–6 weeks), and superior quality of life compared to EPP. Extrapleural pneumonectomy remains a valid option for highly selected, younger, fit patients but is increasingly reserved for cases where P/D is technically infeasible or where specific disease patterns favor aggressive en bloc resection.

The best surgery is paired with chemotherapy (pemetrexed + cisplatin) and performed at a high-volume mesothelioma treatment center by experienced surgical oncologists. Your choice of surgeon and institution may be as important as the surgical procedure itself. Ask your team detailed questions about their experience, outcomes data, and planned multimodal approach. If your mesothelioma resulted from asbestos exposure at work, you may be eligible for compensation through trust funds or litigation—consult with a mesothelioma attorney to explore your options while pursuing the best surgical and medical care.